Sulfur Hexafluoride (SonoVue)
Diagnostic ultrasound contrast agent (microbubble suspension)
Sulfur Hexafluoride (SonoVue)
Forms and strengths
Form: TabletStrength: 25 mg lyophilized powder per vial, reconstituted to 48 micrograms/mL (8 microlitres/mL)
References
Indication
- SonoVue is used during echocardiography to improve visualization of the heart chambers and the endocardial border, helping assess left ventricular wall motion in patients with suspected or known heart disease.
- SonoVue is used during Doppler ultrasound to improve detection of abnormalities in the cerebral, carotid, peripheral, abdominal, and renal arteries, and in the portal vein.
- SonoVue is used, given directly into the bladder, to help evaluate suspected or known vesicoureteral reflux (backward flow of urine toward the kidneys) in children.
- SonoVue should only be used when a standard ultrasound examination without contrast is not conclusive enough.
Pregnancy
- SonoVue has not been adequately studied in pregnant women, and should be used during pregnancy only if clearly needed.
- Animal studies in rats and rabbits at doses well above typical human exposure did not show impaired fertility or fetal harm, but animal data do not always predict effects in humans.
Breastfeeding
- It is not known whether SonoVue passes into human breast milk.
- Caution should be used when giving SonoVue to a breastfeeding woman, since many drugs do pass into breast milk.
Geriatrics
- No overall differences in safety or effectiveness were seen between older and younger adults in clinical studies, though greater sensitivity in some older individuals cannot be ruled out.
- No dose adjustment is specified for older adults.
Pediatrics
- Safety and effectiveness have not been established for use in echocardiography or in Doppler assessment of vessels in children.
- Effectiveness has been established for intravesical use to evaluate vesicoureteral reflux in children, based on published studies in patients from 2 days to 18 years of age.
- The safety of intravesical SonoVue has not been established in children with an active urinary tract infection.
Dosage & Administration
- For echocardiography (endocardial border delineation), SonoVue is given as an intravenous bolus injection over about 1 second; a second injection may be given during the same examination if needed.
- For Doppler assessment of vessels, SonoVue is given as an intravenous bolus injection over about 1 second, except for transcranial Doppler where a slower injection over 2-3 seconds is used to reduce imaging artifacts; a second injection may be given during the same examination if needed.
- Each intravenous injection is followed immediately by a saline flush to help carry the contrast agent into the circulation.
- For ultrasonography of the urinary tract, SonoVue is instilled directly into the bladder through a urinary catheter, followed by saline until the patient feels the urge to urinate; the bladder may be refilled with saline for a second imaging cycle without needing a second dose of SonoVue.
- SonoVue must be freshly reconstituted with the supplied saline immediately before use, shaken vigorously to form a uniform milky white suspension, and used within 6 hours of reconstitution; unused product must be discarded.
- No renal, hepatic, or age-based dose adjustment is specified; SonoVue is a single-use diagnostic product administered by a trained healthcare professional.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- No clinical signs or symptoms of overdose have been reported to date.
- Repeated doses well above typical use were given to healthy volunteers in studies without serious adverse events.
- In the event of overdose, treatment focuses on supporting vital functions and prompt symptomatic therapy.
Common side effects
- Headache may occur.
- Nausea may occur.
- Pain at the injection site may occur.
- Tingling, burning, or numbness (paresthesia) may occur.
- Vomiting may occur.
- In children receiving the bladder (intravesical) form, painful urination, increased urge to urinate, or mild abdominal discomfort related to the catheter procedure may occur.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Severe allergic reactions, including anaphylactic shock, have occurred with SonoVue use.
- Serious heart and lung reactions, including fatalities, have occurred during or shortly after SonoVue injection, most often within 30 minutes of administration.
- Irregular heartbeat (cardiac arrhythmia) can occur.
- Reduced blood supply to the heart (myocardial ischemia) or heart attack has been reported, mostly in patients with underlying coronary artery disease.
- Prolongation of the QT interval on the heart's electrical tracing (ECG) has been observed, which can raise the risk of dangerous heart rhythm disturbances.
- Skin redness, low heart rate, or low blood pressure suggestive of a hypersensitivity reaction have been reported.
- Loss of consciousness and cardiac or cardio-respiratory arrest have been reported rarely.
- Seek urgent medical attention for chest pain, sudden shortness of breath, fainting, swelling of the face or throat, or signs of a severe allergic reaction.
Use with caution
- Use with extreme caution in patients with recent acute coronary syndrome or clinically unstable heart disease, since allergy-like or vessel-dilating reactions can be life-threatening in this group.
- Use with extreme caution in patients with congenital heart defects, serious arrhythmias, recent heart attack with ongoing or unstable angina, active heart infection (endocarditis), or artificial heart valves.
- Use with caution in patients with known QT interval prolongation, low blood potassium, or those taking medicines that prolong the QT interval or certain antiarrhythmic drugs, due to limited experience in these groups.
- Use with caution in patients taking beta-blockers, including eye-drop forms, since these can reduce the effectiveness of emergency treatment if an allergic reaction occurs.
- Use with extreme caution in patients with severe pulmonary disease, since these patients have not been well studied.
- Use with extreme caution in patients with end-stage kidney or liver disease, hyperactive blood clotting states, recent blood clots, or active systemic infection/sepsis, given limited experience in these groups.
- SonoVue is not suitable for patients on mechanical ventilation or with unstable neurological disease, since safety has not been studied in these conditions.
- All patients should be monitored for at least 30 minutes after SonoVue administration to watch for delayed reactions.
Contraindications
- Contraindicated in patients with known right-to-left cardiac shunts, since microbubbles can bypass filtering by the lungs and enter the arterial circulation directly.
- Contraindicated in patients with severe pulmonary hypertension (pulmonary artery pressure above 90 mmHg).
- Contraindicated in patients with uncontrolled systemic high blood pressure.
- Contraindicated in patients with adult respiratory distress syndrome.
- Contraindicated for use together with dobutamine in patients whose cardiovascular instability makes dobutamine itself contraindicated.
- Contraindicated in patients with known hypersensitivity to sulfur hexafluoride or to any ingredient in the formulation, including the container components.
Drug interactions
- No formal drug interaction studies have been conducted with SonoVue in humans.
- Use with medicines known to prolong the QT interval, such as cisapride, erythromycin, certain antipsychotics, and tricyclic antidepressants, should be approached with caution, since an additive effect on heart rhythm cannot be excluded.
- Patients taking beta-blockers, including eye-drop formulations, may have reduced responsiveness to emergency treatment if a hypersensitivity reaction to SonoVue occurs.
- Animal studies found no interaction between SonoVue and common antihypertensive drugs (captopril, propranolol, nifedipine), the anticoagulant heparin, digoxin, isosorbide dinitrate, or the antiplatelet effect of acetylsalicylic acid, but these findings have not been confirmed in dedicated human studies.
Food interactions
- Food timing does not apply to SonoVue, since it is given by intravenous injection or directly into the bladder rather than taken by mouth.
Time of administration
- SonoVue is administered by a trained healthcare professional immediately after reconstitution, timed to the ultrasound examination being performed; it is not a medicine the patient takes on their own schedule.
Storage
- Store the SonoVue kit, before and after reconstitution, at 15°C to 25°C.
- Once reconstituted, use within 6 hours; discard any unused portion.
Patient take-away
- SonoVue is a contrast agent given by a healthcare professional to improve the quality of an ultrasound examination, not a medicine taken at home.
- Serious allergic and cardiopulmonary reactions are possible, so patients are monitored for at least 30 minutes after the injection.
- Tell the healthcare team about any heart conditions, allergies, or medicines (especially beta-blockers) before the procedure.
- Seek urgent care for chest pain, difficulty breathing, or signs of a severe allergic reaction after the procedure.